Tasigna and Alcohol/Food Interactions
There is 1 alcohol/food/lifestyle interaction with Tasigna (nilotinib).
Nilotinib Food/Lifestyle
Major Food Interaction
GENERALLY AVOID: Grapefruit juice may increase the plasma concentrations of nilotinib. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits. Because nilotinib is associated with concentration-dependent prolongation of the QT interval, increased levels may potentiate the risk of ventricular arrhythmias such as torsade de pointes and sudden death.
ADJUST DOSING INTERVAL: Food increases the oral bioavailability of nilotinib. The mechanism of interaction is unknown. Compared to the fast state, nilotinib systemic exposure (AUC) increased by 82% when the dose was given 30 minutes after a high-fat meal. Because nilotinib is associated with concentration-dependent prolongation of the QT interval, increased levels may potentiate the risk of ventricular arrhythmias such as torsade de pointes and sudden death.
MANAGEMENT: Patients treated with nilotinib should avoid consumption of grapefruit, grapefruit juice, and any supplement containing grapefruit extract. In addition, no food should be consumed for at least 2 hours before and 1 hour after a nilotinib dose.
References (1)
- (2007) "Product Information. Tasigna (nilotinib)." Novartis Pharmaceuticals
Switch to consumer interaction data
Tasigna drug interactions
There are 810 drug interactions with Tasigna (nilotinib).
Tasigna disease interactions
There are 8 disease interactions with Tasigna (nilotinib) which include:
- pancreatitis
- QT prolongation
- cardiovascular disease
- fluid retention
- bone marrow suppression
- electrolyte abnormalities
- hepatic impairment
- lactose intolerance
More about Tasigna (nilotinib)
- Tasigna consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (30)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- Generic availability
- FDA approval history
- Drug class: BCR-ABL tyrosine kinase inhibitors
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Hydrea
Hydrea is used for chronic myelogenous leukemia, head and neck cancer
Sprycel
Sprycel is used to treat chronic myeloid leukemia and acute lymphoblastic leukemia. Learn about ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Gleevec
Gleevec is targeted cancer therapy for specific types of leukemia (blood cancer), bone marrow ...
Cytoxan
Cytoxan is used for acute lymphocytic leukemia, acute nonlymphocytic leukemia, breast cancer ...
Scemblix
Scemblix (asciminib) is an oral kinase inhibitor that may be used to treat adults with a type of ...
Bosulif
Bosulif is a kinase inhibitor that may be used to treat adults and some children aged 1 year and ...
Ponatinib
Ponatinib is used to treat chronic myeloid leukemia and Philadelphia chromosome positive acute ...
Dasatinib
Dasatinib is used to treat Philadelphia chromosome-positive chronic myelogenous leukemia (CML) ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.